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Cognitive impairment is a common and seriously debilitating symptom of various mental
and neurological disorders including autism, attention deficit hyperactivity disorder,
multiple sclerosis, epilepsy, and neurodegenerative diseases, like Alzheimer’s disease.
In these conditions, high prevalence of epileptiform activity emerges as a common
pathophysiological hallmark. Growing body of evidence suggests that this discrete but
abnormal activity might have a long-term negative impact on cognitive performance due
to neuronal circuitries’ remodeling, altered sleep structure, pathological hippocampo–
cortical coupling, and even progressive neuronal loss. In animal models, epileptiform
activity was shown to enhance the formation of pathological amyloid and tau proteins
that in turn trigger network hyperexcitability. Abolishing epileptiform discharges might
slow down the cognitive deterioration. These findings might provide basis for therapeutic
use of antiepileptic drugs in neurodegenerative cognitive disorders. The aim of our
review is to describe the data on the prevalence of epileptiform activity in various
cognitive disorders, to summarize the current knowledge of the mechanisms of epileptic
activity in relation to cognitive impairment, and to explore the utility of antiepileptic
drugs in the therapy of cognitive disorders. We also propose future directions for drug
development and novel therapeutic interventions targeting epileptiform discharges in
these disorders.
Keywords: neurocognitive disorder, epileptiform activity, electroencephalography, cognitive decline, memory
consolidation, antiepileptic drugs
INTRODUCTION
Cognitive impairment is a common symptom of various neurological and psychiatric disorders
including autism spectrum disorder (ASD), schizophrenia, attention deficit hyperactivity disorder
(ADHD), multiple sclerosis (MS), and major neurocognitive disorders (NCDs). The cumulative
prevalence of these conditions is ∼50% in developed societies creating prominent medical and
social burden. While the mentioned diseases differ significantly in their symptoms and pathological
background, diminished memory function is a common characteristic.
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The association between epilepsy and the above-mentioned
diseases evoked a remarkable interest in the medical literature
highlighting various hypotheses and explanations of bidirectional
connections. Seemingly, all these syndromes increase the risk for
epileptic seizures.
In ASD, reports agree that patients have increased incidence
for epileptic seizures ranging from 5 to 38% (Hara, 2007).
Symptoms of ADHD are highly common in children affected
by epilepsy, and epilepsy is predominantly associated with
inattentive type of ADHD (Plioplys et al., 2007). Other
studies proposed that children with attention problems have
a two–threefold increase for unprovoked seizure occurrence
(Austin and Caplan, 2007).
Recently, it has been established that epilepsy is a frequent
comorbidity in various forms of NCD (Horváth et al., 2016).
Studies on familial AD steadily demonstrate that seizures affect
approximately half of patients (Zarea et al., 2016). A study
of Beagle et al. demonstrated ∼15% cumulative probability of
developing seizures by patients with diffuse Lewy-body dementia
(DLB) and 3% by patients with frontotemporal degeneration
(FTD) (Beagle et al., 2017). Furthermore, epileptic patients
also have a higher chance for late life neurocognitive disorders
(Subota et al., 2017).
While numerous studies investigated the link between
epileptic seizures and cognitive disorders, reports on epileptiform
activity between seizures [interictal epileptiform activity (IEA)]
or without seizure activity [subclinical epileptiform activity
(SEA)] are underrepresented. While classic epileptology focused
on the accurate control of seizures, in recent years, growing
body of evidence suggests that IEA might have harmful effect
on cognitive functions (Glennon et al., 2016; Hu et al., 2016;
Meekes and Jennekens-Schinkel, 2018). It is intriguing to
analyze the potential role of SEA as well, since SEA shows
similar electrographic features as IEA and the above-mentioned
cognitive disorders share another hallmark: the prevalence of
SEA is elevated in all conditions.
The aim of our opinion review is to describe the results of
studies on the prevalence of IEA and SEA in the various forms
of cognitive disorders, to summarize the current knowledge
on the effect of epileptiform discharges on cognitive functions,
and to propose new directions for therapeutic interventions
targeting cognitive decline. To increase the accuracy and novelty
of our research, we analyzed studies published later than
2000, and in the prevalence and therapy sections, we included
reports on humans only.
PREVALENCE OF SEA AND IEA IN
COGNITIVE DISORDERS
Major Neurocognitive Disorders
NCDs represent 80–100 various conditions with progressive
neurodegenerative process. AD is the leading cause of cognitive
decline by the elderly affecting 37.5 million people worldwide,
and this number is expected to triple by 2050 (Abbott, 2011). The
first symptoms of AD—as the impairment of episodic memory
and difficulty in spatial orientation—occur usually at age of
60–70. During the 6–8 years of disease course, patients lose
other cognitive skills including orientation, communication, and
language skills and finally the ability of self-care (Cummings and
Cole, 2002). The pathological hallmark of AD is the accumulation
and progressive spread of misfolded amyloid and tau proteins
(Ittner and Götz, 2011). Since we are not able to significantly
slow down the progression of cognitive deterioration (Cummings
and Cole, 2002), there is a clear need to find possibly modifiable
factors of AD, especially in the early phases of the disease.
A recently recognized contributor to AD progression is epileptic
activity. Numerous human studies highlighted that AD patients
have a higher chance to develop epileptic seizures (Horváth
et al., 2016). IEA was analyzed in three studies with routine
electroencephalogram (EEG) identifying interictal epileptiform
activity in third of AD patients who presented with epileptic
seizure (Rao et al., 2009; Cretin et al., 2016; Sarkis et al., 2016).
In two sleep EEG studies, IEA rate was 62% (Vossel et al.,
2013) and 80% (Horváth et al., 2018b) in patients with clinical
history of seizures. In these studies, IEA appeared mainly over
the frontotemporal areas with a left-side dominance (Rao et al.,
2009; Vossel et al., 2013; Cretin et al., 2016; Sarkis et al., 2016;
Horváth et al., 2018b). Temporal occurrence of IEA was analyzed
only in two studies: in the study of Vossel et al. (2013), 10% of IEA
was detected during wakefulness and 64% appeared exclusively
in stage2 or deeper sleep, while in our previous report, 82% of
IEA was associated with sleep and 55% was detected in deep sleep
(Horváth et al., 2017b).
There are only a few studies analyzing the occurrence of SEA
in AD. Liedorp at al. found epileptiform discharges in only 3%
of 1,674 AD patients (Liedorp et al., 2010) using 30 min long
daytime EEGs. Vossel et al. revealed SEA in 6% of 113 AD and
MCI patients evaluating daytime routine EEGs in 91% and serial
or long-term EEGs in 7% of the patients (Vossel et al., 2013). In
another study of Vossel et al. using magnetoencephalography and
sleep EEG, SEA was found in 42% of AD patients who have never
experienced epileptic seizure before (Vossel et al., 2016). They
analyzed the temporal distribution of SEA as well showing that
epileptic activity occurs almost completely (90%) during sleep
and mainly over the temporal regions. This is in line with our
previous reports showing the important role of sleep EEG in the
detection of SEA in AD (Horváth et al., 2017b, 2018a). It should
be noted that in Vossel’s study from 2016, SEA was associated
with faster deterioration of cognition determined by Mini-Mental
Score Examination (Vossel et al., 2016). Moreover, studies also
suggest that AD and mild cognitive impairment (MCI) patients
with SEA have an earlier onset of cognitive decline being usually
associated with more aggressive forms of AD that show faster
progression (Vossel et al., 2016; Horváth et al., 2018b). Table 1
summarizes the AD studies on the prevalence of IEA and SEA.
DLB is the second most common type of dementia
accompanied by changes in behavior, cognition, movement,
sleep, and the autonomic functions (Savica et al., 2013). The
major symptoms are the rapid eye movement sleep (REM)
sleep behavior disorder, memory loss, and visual hallucinations
(McKeith, 2002). Furthermore, marked fluctuations in attention
or alertness, parkinsonism (slowness of movement, troubled
walking, or rigidity), and dysfunction of autonomic nervous
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TABLE 1 | Prevalence of epileptiform discharges in Alzheimer’s disease.
References N Study design EEG-type ED (%)
Rao et al., 2009 39 Retrospective, epileptic AD patients Routine (74%) or no EEG (26%) 38% (IEA)
Cretin et al., 2016 13 Retrospective, epileptic MCI patients Routine 100% (IEA)
Sarkis et al., 2016 77 Retrospective, epileptic AD patients Routine 22% (IEA)
Vossel et al., 2013 54 Retrospective, MCI + AD patients Routine and serial 62% (IEA), 6% (SEA)
Horváth et al., 2018b 42 Prospective 24 h 20% (IEA), 28% (SEA)
Liedorp et al., 2010 1,674 Retrospective – 3% (SEA)
Vossel et al., 2016 33 Prospective, non-epileptic AD patients 24 h + magnetoencephalography 42% (SEA)
N, number of patients; MCI, mild cognitive impairment; ED, epileptiform discharge; IEA, interictal epileptiform activity; SEA, subclinical epileptiform activity
system (orthostatic hypotonia, constipation) are also present
(McKeith, 2002). An important diagnostic hallmark is the
hypersensitivity for antipsychotic drugs (McKeith, 2002). The
major pathological finding is the widespread accumulation of
alpha-synuclein protein (Hishikawa et al., 2003). Reports on
DLB-related epilepsy are less frequent compared to AD; however,
a recent paper depicts that DLB patients are susceptible for
seizures similarly to AD patients (Beagle et al., 2017). Another
study using postmortem approach identified myoclonus with
the retrospective analysis of clinical records in 21.7% of DLB
patients, and it was associated with earlier onset of cognitive
decline (Morris et al., 2015). While reports on IED or SEA in DLB
are absent, considering that DLB patients might have a similar
prevalence of seizures than AD patients, analyzing IED/SEA in
DLB is an important future direction.
FTD is a heterogeneous condition encompassing five types
of dementia including behavior and language-dominant lobar
degenerations (behavioral variant, semantic variant primary
progressive aphasia, and non-fluent variant primary progressive
aphasia) and motor dominant disorders (corticobasal syndrome,
progressive supranuclear palsy) (Bang et al., 2015). Initial
symptoms usually appear by adults in their fifth or sixth decade of
life (Bang et al., 2015). The histological finding is the progressive
accumulation of tau, tdp-43, and fus proteins (Bang et al.,
2015). FTD patients tend to have also higher risk for epileptic
seizure (Beagle et al., 2017; Arnaldi et al., 2020); however, there
is only one case in the literature focusing on the importance
of epileptic activity in FTD. With the help of foramen ovale
electrodes, SEA was detected in a seizure-free patient with FTD
that could have caused the daily variability in her cognitive
behavior (Horváth et al., 2017a). Since the number of reported
cases on IEA/SEA on FTD is still small, further investigation is
necessary (Chan et al., 2004).
Huntington disease is an autosomal dominant
neurodegenerative disorder that is characterized by involuntary
movements, cognitive decline, and personality changes (Bates
et al., 2015). Reports on patients with adult onset showed that
prevalence of seizures is similar to the general population (Sipilä
et al., 2016). However, epileptic seizures and epileptiform activity
occur in 30–40% of patients in the rarer juvenile type (J-HD),
which appears in young persons under 21 years of age (Cloud
et al., 2012). Currently, there are only a few studies in the
literature solely investigating SEA or IEA in Huntington disease.
A review of Landau and Cannard (2003) analyzed 23 previously
published cases of J-HD patients. Epileptiform abnormalities
were noted in 17 (74%). In 10 cases, they were associated with
overt epileptic seizures, so the prevalence of IEA was 44%. In
seven cases (30%), SEA was detected. Nine patients showed
generalized discharges having polyspike and wave activity, while
eight others had focal or multifocal epileptiform discharges
with posterior predominance. The limitation of this study
is that the diagnosis of J-HD was not genetically confirmed.
Another study analyzed the pattern of IEA of a J-HD patient
with epileptic seizures and described the occipital intermittent
rhythmic delta activity as the major hallmark of epileptic activity
(Ullrich et al., 2004).
To conclude, patients with various forms of NCD tend to be
more vulnerable for epileptic seizures, however, prevalence data
show high variability. While SEA is detectable in approximately
17% of AD patients, studies on other NCD forms are scarce. The
role of SEA in the accelerated progression of AD draws attention
to the need for further investigations.
Multiple Sclerosis
MS is a heterogeneous demyelinating disease of the central
nervous system involving inflammatory processes not only of the
white matter but also the juxtacortical and cortical areas. Recent
studies also highlight that MS should be also considered as a
neurodegenerative disorder (Ziemann et al., 2011). Attention has
been mostly focused on clinical seizures, as seizures might occur
at any stage of MS. Sponsler and Kendrick-Adey conducted the
most extensive review on assessing prevalence of seizures among
MS patients by compiling results of 25 scientific papers (Sponsler
and Kendrick-Adey, 2011). They found that about 2% of MS
patients experienced seizures. A study of 36 patients found that
early-onset MS frequency was significantly higher in patients with
epileptic seizures as compared to those without epilepsy (Durmus
et al., 2013). Epileptic events might be a consequence of edema
surrounding the lesions, disease-modifying drugs lowering the
epileptic threshold, or the reduced cortical thickness as a result
of disease course (Geurts et al., 2005; Cheng et al., 2012;
Calabrese et al., 2017). A study by Calabrese et al. (2008) reported
intracortical lesions in 90% of epileptic patients with relapsing–
remitting MS (RRMS), whereas only in 48% with RRMS without
epilepsy. In another study by his group, the most affected gray
matter lesions in RRMS epileptic patients were the hippocampus
(14.2%), the lateral temporal lobe (13.5%), the cingulate (10.0%),
and the insula (8.4%) (Calabrese et al., 2017). Lund et al.
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suggested that epilepsy in MS should be classified as symptomatic
focal epilepsy due to the nature of cortical lesions (Koch et al.,
2008; Lund et al., 2014).
Available data on prevalence and background of IEA and
SEA in multiple sclerosis are limited. SEA could potentially
be a major reference point in guiding a clinician, however, no
studies exist that focus solely on SEA in MS patients. EEG
abnormalities reported in MS can be diffuse asynchronous theta
activity, synchronous rhythmic slow waves, focalized flattened
EEG patterns (Striano et al., 2003), or less frequently periodic
lateralized epileptiform discharges, which are mostly seen in
acute exacerbations of the disease (Lawn et al., 2001; Nyquist
et al., 2001; Gandelman-Marton et al., 2003). Table 2 lists some
of the studies that looked at EEG abnormalities distinguishing
based on epileptiform and non-epileptiform pathological EEG
events. However, most of these studies had varying methodology
and looked at alterations in MS patients who already were known
to have at least one seizure when they all analyzed IEA. IEA
was found in 3.9–86.9% of the patients representing the great
variability of the study methods (e.g., EEG technique and length
of recording, retrospective vs. case–control studies, sample sizes
of 23 patients vs. 29,165 patients). Only three studies analyzed
SEA independently, suggesting ∼7–8% prevalence. Bustuchina
postulated a bidirectional relation between MS and epileptic
activity and suggested that MS might be a network disease, and
so emphasis should be put on both entities for best therapeutic
outcome (Bustuchina Vlaicu, 2019).
Autism Spectrum Disorder
ASD is an umbrella term for several neurodevelopmental
conditions defined by the Diagnostic and Statistical Manual
of Mental Disorders, fifth edition (DSM-V) classification,
which share clinical manifestations in varying degrees. Such
manifestations are impairment in sociability, communication
deficits, non-verbal interaction issues, restricted range of
interest, repetitive behavior, and impairment of intellectual and
behavioral flexibility (Tuchman and Rapin, 2002; American
Psychiatric Association, 2013). Pathophysiological background
of this heterogeneous syndrome originates in the neural circuit
disconnection between the association cortex of the frontal
lobe and the higher-order multimodal temporal lobe (Assaf
et al., 2010; Belger et al., 2011). SEA and IEA might be
one of the biomarkers of malfunction of these involved
intrinsic connectivity networks. Table 3 summarizes studies
that assessed epileptiform discharges in patients diagnosed with
ASD. Prevalence of epileptiform activity is reported in 21–75%
of patients. Epilepsy has also been associated with ASD, with
a rate of 5–39.2% (Hara, 2007; Ghacibeh and Fields, 2015).
A study by Clarke et al. found that 32% of their epileptic subjects
met the criteria of ASD, however, authors used questionnaires
only, and confirming clinical diagnostic tests were not applied
(Clarke et al., 2005).
Several studies have suggested that increasing severity of
autistic symptoms may be associated with higher likelihood of
epileptic abnormalities (Elsayed and Sayyah, 2012; Mulligan and
Trauner, 2014). EEG abnormalities have also been associated
with autistic regression, lower intellect, delayed motor, and social
development in the first year of life (Hrdlicka et al., 2004). This
hypothesis is supported by Nicotera et al. as well (Gennaro
Nicotera et al., 2019). In their study, epileptiform discharges
were also significantly associated with hyperactivity, aggressive
behaviors, self-harm behavior, and severe language impairment.
Giannotti specifically investigated sleep patterns of ASD children
and found that 64.42% of the patients had active sleep problems
and also that disrupted sleep was associated with more severe
disease course (Giannotti et al., 2008). Regarding the prevention
of the syndrome, a 10-year follow-up study conducted by Hara
showed that although 18% of the non-epileptic group exhibited
SEA on EEG, 68% of epileptic group revealed SEA findings before
the onset of epilepsy (Hara, 2007). He suggested that routine
EEGs could predict developing epilepsy in the future.
When we consider treating SEA, Chez et al. found that
regimental administration of valproic acid normalized the EEG in
46.6% of ASD diagnosed with SEA (Chez et al., 2006). However,
we lack studies on EEG changes of ASD patients following ASD
therapy, and studies on behavioral aspects could not prove that
use of anticonvulsants provided better outcome than placebo
(Hirota et al., 2014).
Based on the above, we are still not confident what SEA
means on an EEG regarding pathodevelopment of ASD patients,
but there are correlations and associations made. Currently
EEG screening and prophylactic anticonvulsant treatment is
not recommended in ASD (Swatzyna et al., 2019), as we are
not certain about the clinical importance of these epileptiform
alterations seen on EEG and how clinical outcome would be
affected by such medication regime. However, clinicians could
TABLE 2 | Prevalence of epileptiform discharges in multiple sclerosis.
References N Study design EEG type ED (%)
Dagiasi et al. (2018) 62 Retrospective Routine 38 (IEA)
Benjaminsen et al. (2017) 431 Retrospective Routine 3,9 (IEA)
Calabrese et al. (2017) 23 Case–control Routine 86,9 (IEA)
Kelley and Rodriguez (2009) 168 Review – 32,7 (IEA)
Nyquist et al. (2001) 43 Retrospective Sleep–awake 44.2 (IEA)
Sponsler and Kendrick-Adey (2011) 29,164 Review – 1.95% (SEA)
Cheng et al. (2012) 93 Retrospective Routine 8.6% (SEA)
Lund et al. (2014) 364 Retrospective Routine 7.4% (SEA)
N, number of patients; ED, epileptiform discharge; IEA, interictal epileptiform activity; SEA, subclinical epileptiform activity.
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TABLE 3 | Prevalence of subclinical epileptiform activity (SEA) in autism spectrum disorder (ASD).
References N Study design EEG-type ED (%) Localization
Hughes and Melyn (2005) 59 Case–control Routine + photic stim 75 Generalized, 59% bilateral spikes and 54%
slow-wave complexes
Kim et al. (2006) 32 Prospective cohort Video-EEG 59 Focal/multifocal sharp waves, generalized
paroxysmal fast activity
Hrdlicka et al. (2004) 77 Prospective cohort Polysomnography 38.1 –
Akshoomoff et al. (2007) 60 Prospective cohort Routine 32 –
Yasuhara (2010) 1014 Prospective cohort Routine
polysomnography
85.8 Frontal spikes 65.6%, multifocal spikes < 10%
Gennaro Nicotera et al. (2019) 69 Routine Routine 26.08 Focal spikes, 55.55%; multifocal and diffuse
spikes, 44.44%
Mulligan and Trauner (2014) 101 Retrospective Routine 59.4 –




Hara (2007) 130 Retrospective follow-up Routine 21 –
Chez et al. (2006) 889 Retrospective 24-h 60.7 Right temporal spikes, 21.5%; bilateral
temporal spikes, 20.2%; generalized spike
wave, 16.2%
Elsayed and Sayyah (2012) 47 Case–control Routine 51.1 Focal frontal, occipital, temporal spikes
Hartley-McAndrew and Weinstock (2020) 123 Retrospective Routine 30 –
N, number of patients; ED, epileptiform discharge.
consider obtaining a longer EEG examination and overnight
EEG video monitoring. Certainly, applying long-term EEG is
crucial, as Chez et al. showed that 5% of EEG abnormalities may
have been missed in patients who had a negative, routine EEG
previously. Chez et al. (2006) and Gennaro Nicotera et al. (2019)
found that, when present, EEG abnormalities were detectable
predominantly during sleep. For quality assessment prospective,
randomized trials are needed, with clear methodology, and with
choices of instrumentation that maximize the amount of data
gained from the study population.
ADHD
ADHD is a syndrome defined by the American Psychiatric
Association DSM-V as a persistent pattern of inattention and/or
hyperactivity–impulsivity that interferes with functioning or
development. In its presentation, we distinguish predominantly
hyperactive–impulsive, inattentive, or combined subtypes
(American Psychiatric Association, 2013). Worldwide the
syndrome affects around 5% of children and 2.5% of adults
(Polanczyk et al., 2014). EEG and functional imaging research on
anatomical aspect of the disease shows involvement of the frontal
cortex (Parisi et al., 2010; Schulz et al., 2012; Zaimoglu et al.,
2015), particularly the dorsal anterior cingulate cortex manifested
by decreased function of this brain area during inhibitory task
control (Bush et al., 2005) and EEG paroxysmal abnormalities
(Kanemura et al., 2013). Data suggest a pathophysiological and
comorbid overlap between ADHD and epilepsy (Dunn and
Kronenberger, 2006; Kaufmann et al., 2009; Salpekar and Mishra,
2014), a study of 76 children with epilepsy found that 31% of
them had ADHD compared to 6% in the healthy control group
(Hermann et al., 2007). Some studies found that in epileptic
children, inattentive subtype is dominating while the combined
type in those without epilepsy (Dunn and Kronenberger, 2006;
Hermann et al., 2007; Socanski et al., 2010; Kanemura et al.,
2013); however, others failed to show such relation (Lee et al.,
2016). Although there is a challenge of distinguishing EEG
abnormalities of ADHD and epilepsy in the same patient, there
has been emerging focus on investigating SEA and their relation
to transient cognitive impairment in this subgroup of children
(Aldenkamp and Arends, 2004; Schubert, 2005).
Table 4 summarizes the prevalence of SEA among studies,
which varies from 4.9 to 53.1%. Most studies are retrospective
and used routine EEG. Epileptic activity in ADHD is commonly
detected as generalized 3-Hz spike-and-wave discharges
and paroxysmal abnormalities such as focal spikes (frontal,
midtemporal, rolandic or parietal, occipital) (Holtmann et al.,
2003; Schubert, 2005; Kanemura et al., 2013). A review by
Salpekar et al. pointed out that an increase in theta waves in
frontal regions seems to be a consistent EEG abnormality in
this subgroup of patients and that alpha wave asymmetry and
higher theta-to-beta ratio have also been reported (Salpekar
and Mishra, 2014). The effect of antiepileptic drugs (AED) in
patients with SEAs seems to show behavioral improvement
in those children with frontal spikes but less so in case of the
age-dependent Rolandic spike abnormalities (Holtmann et al.,
2003; Schubert, 2005; Kanemura et al., 2013). Furthermore,
SEA also had a positive predictive value of 14% for developing
seizures in a group of 347 ADHD children (Richer et al., 2002).
It should be noted that SEA was only seen in some of the
patients after photic stimulation or hyperventilation in the study
of Richer et al. (2002).
In Table 4, we collected the most recent studies on prevalence
of epileptiform events. The study of Silvestri et al. (2007) reported
the highest prevalence of SEA (53.1%) in their prospective
cohort of 42 patients. It is noteworthy that this was the only
study that used polysomnography for the evaluation. SEAs are
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TABLE 4 | Prevalence of subclinical epileptiform activity (SEA) in attention-deficit hyperactivity disorder (ADHD).
References N Study design EEG type ED (%) Localization
Kanemura et al. (2013) 46 Prospective cohort Routine + photic stim 20 min 34.8 100% focal
Lee et al. (2016) 180 Retrospective Routine 16.1 8.3% general 7.7% focal–frontal, Rolandic
Hughes et al. (2000) 176 Prospective Routine 1 h with stimulation 30 24% focal 13% bifrontal
Hemmer et al. (2001) 234 Retrospective Routine awake 15.4 60% focal, (5,6% Rolandic overall)
Millichap et al. (2011) 612 Retrospective Routine 26.1 42.9% focal 41.7% generalized
Richer et al. (2002) 347 Retrospective Routine 20 min + photic stim 6.1 –
Zaimoglu et al. (2015) 148 Prospective Routine 1 h wake–sleep 26.4 Frontal, centrotemporal
Silvestri et al. (2007) 42 Prospective cohort Sleep EEG (polysomnograpy) 53.1 28.2% centrotemporal, 12.5% frontal
Matoth et al. (2002) 126 Prospective cohort Routine with stimulation 5 –
Socanski et al. (2010) 517 Retrospective cohort Routine 7.5 53.9% generalized, 41% focal, 1.7% Rolandic
N, number of patients; ED, epileptiform discharge.
known to be more frequent during sleep, however, the capture
of these abnormalities is extremely problematic on a routine 20–
30 min long EEG. It is an open question whether or not the
subgroup of ADHD patients with SEA would benefit from AEDs
by preventing progression of disease and decline of cognitive
function. To conclude, several studies have suggested that EEG
can be used in specific populations to exclude more crude
pathology, albeit others did not support this view (Hemmer et al.,
2001; Matoth et al., 2002; Socanski et al., 2010; Millichap et al.,
2011). Clearly, there is an important role of investigating SEAs
in central nervous system (CNS) pathology, such as ADHD.






Neurodegeneration is a progressive loss of function and
structure of neural cells leading to the death of neurons and
glial cells (Spillantini and Goedert, 2013). The progressive
decline of cognitive functions in neurodegenerative disorders
is in line with the spreading of the accumulated misfolded
proteins that is the major neuropathological hallmark of these
disorders. The toxic proteins are different in the various forms of
dementia (taupathies, amyloidopathies, synucleinopathies, etc.),
however, they all have harmful effect on cellular membranes,
mitochondrial functions, axonal transport, synaptic strength,
and on neural survival in oxidative stress (Taylor et al.,
2002). Misfolded proteins also change the physiological
neuroinflammatory processes activating proinflammatory
and neurotoxic mediators (Giovannini et al., 2002). As a
summary of induced changes, protein misfolding associates
with rapid neuronal death. Spatial distribution of pathological
proteins varies among neurodegenerative disorders leading to
different clinical presentations (e.g., entorhinal cortex is first
to degenerate in AD, and substantia nigra is first in DLB and
Parkinson’s disease). In MS, neurodegeneration also occurs
in an interaction with autoimmune inflammatory responses
targeting myelin and oligodendrocytes (Ellwardt and Zipp,
2014). Neurodevelopmental factors ending in decreased neural
survival are crucial in the pathogenesis of ASD because of
genetic mutations of synaptogenic, inflammatory moderator
and axon mobility factors (Kalkan et al., 2016; Rani, 2019).
Some studies demonstrated that neurodegeneration occurs in
epilepsy, too (Frantseva et al., 2000; Rao et al., 2006). While
the typical histopathological hallmark of temporal lobe epilepsy
is the neural loss and gliosis detected in the hippocampus,
amygdala, and entorhinal cortex, novel examinations report the
presence of misfolded tau and amyloid proteins as well (Tai et al.,
2016). Furthermore, neuroimaging and physiology data show
progressive gray matter atrophy in the structures of epileptic
network (Bernhardt et al., 2010).
A common feature among epilepsy and all neurodegenerative
disorders is the increased cortical excitability (Di Lazzaro et al.,
2004; Gilbert et al., 2004; Takarae and Sweeney, 2017). Growing
body of evidence supports that increased excitability precedes
neurodegeneration in various diseases. Vucic and Kiernan
(2006) and Vucic et al. (2008) reported reduced short-interval
intracortical inhibition prior to the symptom onset in patients
with amyotrophic lateral sclerosis and with other motoneuron
disorders using transcranial magnetic stimulation. According to
the studies of Vossel et al. (2013), the occurrence of seizures is
increased years before the initial symptoms of AD.
Elevated cortical excitability might contribute to
neurodegeneration through excitotoxicity (Mehta et al.,
2013). It refers to a toxic effect, resulting from prominent and
prolonged activation of excitatory neural receptors causing cell
death (Bano et al., 2005). Under normal conditions, glutamate
acting on its postsynaptic receptors [N-methyl-D-aspartate
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA)] causes depolarization and permits the increase in
intracellular calcium. If depolarization is prolonged or glutamate
reaches an excessive concentration in the synaptic cleft, it turns
into a neuron-killing toxin causing the disruption of cellular
osmotic equilibrium (Ong et al., 2013).
The glutamate neurotransmitter system is affected in
many diseases with cognitive symptoms (Figure 1). High
level of calcium permeable AMPA receptors was identified
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FIGURE 1 | The vicious circle of glutamate mediated hyperexcitability and accumulation of misfolded toxic proteins in cognitive disorders. Glutamate
neurotransmitter is altered in all cognitive disorders resulting in overexpression of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and
elevated intracellular calcium signaling. Elevated calcium signal associates to higher release of amyloid oligomers to extracellular space and to increased
phosphorylation of tau oligomers (red arrows). Increased firing of neurons represented by epileptic discharges is a consequence of glutamate-related hyperexcitability
as well. On the other hand, accumulation of amyloid plaques and tau neurofibrils change glutamate receptor expression and induce excessive release of glutamate
from microglial cells and astrocytes (green arrows). The bidirectional pathologic relationship could result in progressive neurodegeneration (black arrows), which is
common hallmark of cognitive disorders.
in amyotrophic lateral sclerosis (Leal and Gomes, 2015).
Inflammation induced, microglia driven excitotoxicity is a
central event in MS (Gonsette, 2008). Elevated cortical glutamate
concentration is a common finding in ASD (Brown et al.,
2013). In AD, amyloid induces excessive glutamate release
from astrocytes (Esposito et al., 2013), blocks the glutamate
transporters of astrocytes responsible for reuptake (Zott et al.,
2019), elevates calcium influx with the increase in depolarization
(Fu et al., 2012), and activates NMDA receptors (Ferreira
et al., 2010). Furthermore, tau might enhance the presynaptic
glutamate release (Decker et al., 2016). Normal apoE function
is essential in the attenuation of glutamate effect; however,
its genetic mutation is the most known risk factor of AD
(Aono et al., 2002). On the other hand, prolonged activation of
NMDA receptors results in elevated production and secretion of
amyloid-beta (Lesné et al., 2005) and in hyperphosphorylation of
tau (Liang et al., 2009). It might explain the elevated phospho-tau
level in surgical samples of temporal lobe epilepsy patients
(Tai et al., 2016).
Since epileptic activity associates to excessive stimulation of
NMDA receptors, it is intriguing to speculate that epileptic
seizures might contribute to the neural loss presented in
various forms of cognitive disorders. Indeed, the presence
of epileptic seizures associates with faster progression of
symptoms in AD (Vossel et al., 2013). However, short-
lasting excitations (IEA and SEA) also associate with increased
glutamate release (Kang et al., 2005), so harmful effect
of epileptic discharges is predictable. It is reinforced by a
study of Dolev et al. (2013), showing that even a 20 Hz
burst activity could increase amyloid burden; by the study
of Bero et al. (2011), showing that neuronal hyperactivity
associates to increased amyloid burden; and by a report of
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Vossel et al. (2016), demonstrating the role of SEA in the
accelerated progression of AD.
Remodeling of Neural Circuitry
Balance between excitatory glutamatergic and inhibitory
GABAergic activity in the large functional networks of the
brain is crucial in all cognitive functions (Sengupta et al., 2013).
Reduction in inhibition or increase in excitation has a key role in
ictogenesis (Bonansco and Fuenzalida, 2016). Local GABAergic
sprouting limits the spreading of epileptic activity to distant areas
(Sutula, 2002), relatively disconnecting the epileptogenic zone
from connected brain structures. Connectivity studies support
the pathological findings describing increased intrahippocampal
and decreased hippocampo-cortical connectivity in patients with
mesio-temporal lobe epilepsy (Warren et al., 2010; Engel et al.,
2013). As seizures propagate and the epileptic network extends,
altered hippocampo-cortical structural connectivity could lead
to less synchronized global networks, to impaired organization
of rhythmic brain activities, and finally to random organization
of physiological networks (Luo et al., 2012; Figure 2).
Growing body of evidence suggests that IEA spreads in the
same pathological network as epileptic seizures, however, the
underlying aberrant activity does not reach the seizure threshold
(Dzhala and Staley, 2003). This hypothesis is supported by clinical
observations of transient cognitive impairment (TCI) observed
after IEA. TCI is characterized by a brief temporary deficit in
memory encoding, attention, communication, or visuospatial
abilities (Holmes and Lenck-Santini, 2006). If IEA is frequent,
epileptic activity could induce long-lasting and distant changes
in brain functioning (Caciagli et al., 2014). It is supported by
the findings of Gelinas et al. (2016) showing that IEA shows
a coupling with spindles via cortical downstates. Studies using
functional MRI reinforced these suggestions, demonstrating
spike-related changes in blood–oxygen-level-dependent imaging
FIGURE 2 | Remodeling or hippocampo-cortical circuitry as a result of
epileptic discharges. (A) Physiological organization of hippocampo-cortical
connections with numerous, strong local connections and less and weaker
distant associations. (B) As a result of epileptic discharges, intrahippocampal
connectivity is increased, and the strength and number of long distant
connections are decreased. The remodeling of network circuitry leads to a
relative isolation of hippocampus from cortical areas reducing the efficacy of
hippocampo-cortical coupling.
(BOLD) signal even at distant cortical sites (Federico et al., 2005).
Reports applying EEG connectivity analysis revealed similar
findings demonstrating that functional connectivity is increased
in the epileptic network during IEA similarly to seizure-related
alterations, while it is reduced between epileptic and functional
networks such as default mode network (DMN) (Bettus et al.,
2008; Fahoum et al., 2013). Noticeably, these changes become
permanent in a long-lasting disease and remain independent
from ongoing IEA (Luo et al., 2011).
Substantial alterations of large neural networks have been
shown in all conditions. Elevated intrahippocampal activity is
depicted in the prodromal stages of AD (in amnestic mild
cognitive impairment) (Bakker et al., 2012) correlating with
cortical thinning (Putcha et al., 2011) and with disconnection
to other neural networks including DMN (Pasquini et al.,
2015). Similar findings showing local increase in connectivity
and reduction in global connectivity have been described in
various forms of dementia including DLB and FTD (Agosta
et al., 2013; Dauwan et al., 2016). Hyperactivity within
large-scale brain networks and decreased between-network
connectivity is a core finding in pediatric ASD studies (Cerliani
et al., 2015; Nomi and Uddin, 2015). Increased within-
network hyperconnectivity has been described in the frontal
areas of ADHD patients (Wang et al., 2009) with a loss of
long distant connections. Interestingly, AD-like changes in
hippocampo-cortical connectivity (increase in intrahippocampal
connectivity and decrease in global connectivity) have been
demonstrated in MS patients with memory impairment; however,
they parallelly identified reduction in hippocampal activation
(Hulst et al., 2015).
Disruption of Sleep-Related Memory
Consolidation Process
Sleep occurs in all vertebrates in regular intervals, and it is
homeostatically regulated. It is well known that sleep deprivation
has a harmful effect on the physical and mental health including
severe changes in hormonal, homeostatic, and temperature
regulation, higher occurrence of infections, and dysfunction of
cardiovascular control (Shahar et al., 2001). Human sleep is
distinguished into non-REM and REM sleep. The dual process
hypothesis postulates that REM sleep is crucial in implicit
memory formation, while non-REM sleep, especially episodes
characterized by slow-wave electric activity (slow-wave sleep or
SWS) is mandatory in the establishment of episodic memory
(Diekelmann and Born, 2010). The widely accepted two-stage
memory model differentiates brain structures into areas with
short-term memory capacity having an encoding function and
into regions serving as long-term storages (Walker, 2005). The
memory consolidation process involves the repeated reactivation
of short-term stored memory items (freshly developed synaptic
connections) during offline periods (e.g., SWS) and the
strengthening and adaptation of memory fragments into long-
term storages (Stickgold, 2005).
The anatomical structure for the interplay is the network
between hippocampus and cortical areas. In human SWS,
EEG shows 0.5–4 Hz slow oscillations with dynamic
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alterations of neuronal membrane depolarization (upstates)
and hyperpolarization (downstates) (Csercsa et al., 2010).
Dynamic changes reveal an opportunity for the reduction in
weaker synaptic connections parallel with the reinforcement
of stronger ones, known as synaptic downscaling (Tononi
and Cirelli, 2006). Neurons during SWS show widespread
synchronization in cortico-cortical, thalamo-cortical, and
hippocampo-cortical networks (Dang-Vu et al., 2008). High
synchrony is reinforced by animal and human neurophysiology
studies showing that the top–down controlled phase-locked
co-occurrence of hippocampus generated sharp-wave ripples,
thalamic sleep spindles, and cortically induced slow waves
(Maingret et al., 2016).
An epileptic spike is shorter but similar to sharp wave, and
it associates to faster ripple oscillations than sharp wave (Bragin
et al., 2002). Numerous studies hypothesized that epileptic
discharges linked to fast ripples could interfere with normal
memory process (Halász et al., 2019; Figure 3). Furthermore,
they can also act as dysfunctional (“dummy”) variants of sharp-
wave deteriorating memory consolidation (Gelinas et al., 2016).
The crucial role of sleep-associated IEA in memory formation is
suggested by the following findings: IEA predominantly occurs
in SWS (Bazil, 2000); it associates with longer REM latency (first
occurrence of REM during the night), with reduced duration of
SWS (Miller et al., 2016) and with lower number of physiological
ripples (Jefferys et al., 2012) and negatively affects thalamic
spindle formation (Frauscher et al., 2015).
While sleep changes might have a crucial role in the memory
impairment of epileptic patients, sleep disorders are also highly
prevalent in cognitive disorders. Around 40% of AD patients
suffer from sleep disturbances (Tractenberg et al., 2003), namely,
from nocturnal sleep disruption, increased daytime sleepiness,
insomnia (Rao et al., 2008; Osorio et al., 2011), and sundowning
(agitation and confusion late afternoon) (Volicer et al., 2001).
About 50–83% of DLB patients suffer from REM sleep behavior
disorders (Ferman et al., 2010). In MS, obstructive sleep apnea
(Braley et al., 2014), restless leg syndrome (Manconi et al.,
2007), and moderate or severe insomnia are frequently observed
(Brass et al., 2014). Insomnia is reported in 44–83% of children
with ASD (Miano and Ferri, 2010). Prominent elevation in the
occurrence of restless leg syndrome, periodic limb movement
in sleep, sleep-onset insomnia, nocturnal motor activity, and
obstructive sleep apnea has been highlighted in numerous studies
on ADHD patients (Konofal et al., 2010). Sleep microstructure
seems to be highly impaired as well in cognitive disorders.
Reduced REM sleep, decreased number of sleep spindles,
reduction in SWS, and increase in superficial stages have been
reported in ASD (Richdale and Schreck, 2009). Excessive loss
of SWS is a characteristic hallmark of AD with a reduction in
sleep spindles and K complexes (Petit et al., 2004). Children with
ADHD show lower rate of cyclic alternating pattern and sleep
spindles (Miano et al., 2006; Kirov and Brand, 2014). Thus, the
role of poor sleep in cognitive impairment is not questionable in
cognitive disorders.
FIGURE 3 | Hippocampo-thalamo-cortical coupling in memory consolidation. In physiological memory consolidation process, synchronization of the hippocampus,
thalamus, and neocortex is essential. Hippocampal sharp-wave ripples correspond to the replay of recently stored memory items in the synaptic connections of
hippocampal neurons. Thalamic sleep spindles with a frequency of 12–16 Hz are essential elements of memory formation, synchronizing hippocampal activity with
cortical neurons. Cortical sleep-related slow waves provide the highest synchronization state to facilitate the activation of hippocampal sharp-wave ripples and
thalamic sleep spindles. Epileptic discharges correspond to the pathological transformation of sharp waves coupling with faster high frequency oscillations. The
altered activity disorganizes the architecture of spindles, decreases the normal spindle activity, and induces the formation of dummy spindles with longer duration
and spiky appearance. Cortical slow waves are also reduced, probably due to the spike-inducted cortical hyperpolarization (downstates). Alterations might reduce
the efficacy of memory consolidation process.
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While SWS is reduced in all cognitive disorders, SEA
seemingly still accumulates in deep sleep similarly to epileptic
patients. Approximately 90–100% of epileptic discharges are
detected in SWS in studies examining patients with AD
(Vossel et al., 2016) or with ASD (Chez et al., 2006).
Furthermore, the occurrence of epileptiform discharges on
nocturnal EEG is positively related to higher attention deficit and
higher impulsivity in ADHD patients (Danhofer et al., 2018).
Since epileptic activity compromises the organization of sleep
structure and disturbs the sleep-related memory consolidation
processes, it is intriguing to state that SEA might accelerate the
disorganization of sleep structure and contribute to the decline of
memory functions.
THERAPEUTIC ASPECTS
Current Findings and Recommendations
The primary application of AEDs is to effectively reduce or
eradicate epileptic seizures with an optimal side effect profile.
Approximately 30 types of AEDs are available on the market
with first, second, and third lines of indications regarding the
type of seizures, the age, physical condition, and the current
drug use of the patient. While we do not understand completely
the mechanism of all AEDs, their efficacy is measured as
the extent of decrease in the number of seizures. While we
have tremendous experience and recently updated guidelines
for controlling seizures in epilepsy patients, we have relatively
limited data on the AED selection in cognitive disorders. In
AD, studies are available on levetiracetam (LEV), lamotrigine
(LTG), gabapentin, carbamazepine, valproic acid, phenytoin, and
phenobarbital (Horváth et al., 2016; Vossel et al., 2017). Only
LEV and LTG reached excellent efficacy (60–70% reduction in the
number of seizures in a 1-year follow-up) and tolerability without
cognitive side effects (Belcastro et al., 2007; Cumbo and Ligori,
2010; Lippa et al., 2010). Notably, treatment with LEV resulted
in marginally increased cognitive scores (MMSE and ADAS-
Cog), and application of LTG was associated with significantly
improved mood (Cumbo and Ligori, 2010), but the study was
not placebo controlled. Studies on AED application in other
NCDs for controlling seizures are absent (Horváth et al., 2018a).
According to the current guidelines, the management of seizures
does not differ in other cognitive disorders compared to epilepsy
patients (Myers and Johnson, 2007; Kelley and Rodriguez, 2009;
Felt et al., 2014).
While growing body of evidence supports the central role
of epileptic discharges in cognitive deterioration, studies on
affecting SEA are limited in cognitive disorders. In NCDs, LEV
treatment for 2 weeks significantly improved performance in
pattern separation, but no other cognitive scores of non-epileptic
MCI patients in line with the normalization of hippocampal
and entorhinal cortical activity measured with functional MRI
(Bakker et al., 2015). In the study of Musaeus et al. (2017) using
single-dose LEV, while antiepileptic therapy marginally increased
the power of beta band in AD patients, positive cognitive effect
was not detected. Unfortunately, studies on other forms of NCDs
have not been conducted. Furthermore, most MCI and AD
studies are not double-blind observations and did not use SEA as
a selection criterion or a marker of therapeutic response. Ongoing
clinical trials (e.g., ILiAd, NCT03489044; LAPSE, NCT04004702;
LEV-AD, NCT02002819 studies) on LEV already assess SEA
for the identification of target groups, but results have not
been published yet. In ASD patients without epileptic seizures,
seven placebo-controlled, randomized studies on the use of AED
are available. These studies analyze the utility of valproic acid,
topiramate, LTG, and LEV. Based on the findings of a meta-
analysis, AED did not have a significant effect on behavioral
symptoms, however, studies have not differentiated subgroups of
patients with SEA and were not EEG controlled (Hirota et al.,
2014). In ADHD, only independent, single reports are available
on the use of AED in non-epileptic patients. A study using
valproic acid reported reduction in frontal SEA in 62% of ADHD
patients, and the decrease was correlated with improvements
in ADHD rating scale (Kanemura et al., 2013). In the study of
Öncü et al. (2014), LTG improved mood scores in 78% of ADHD
patients with comorbid bipolar disorder or depression, however,
EEG was not applied. While AED are frequently prescribed in MS
for neuropathic pain, studies on SEA or on cognitive impact were
not conducted (Solaro et al., 2005).
Age-related changes in pharmacodynamics and
pharmacokinetics make AED studies by the elderly complicated.
In the selection of AEDs, safety issues and contraindications
have to be carefully considered in these patients. In previous
studies, the use of AEDs has been associated with elevated
risk for fall (Seppala et al., 2018), stroke (Sarycheva et al.,
2018), fractures (Shen et al., 2014), pneumonia (Taipale et al.,
2019), and adverse drug–drug interactions (Anderson, 2004).
Application of traditional AEDs (e.g., phenytoin, valproic acid)
was associated with unplanned hospital admissions and impaired
motor functions (Lin et al., 2017). Use of carbamazepine
and oxcarbamazepine was attached to adverse cardiac events,
hyponatremia, and sedation (Spina and Perucca, 2002). Thus,
contraindications have to be considered individually.
For the understanding of the potential role of AED in
the therapy of cognitive impairment, double-blind, placebo-
controlled studies are needed in various cognitive disorders.
The detection of SEA with EEG might have a crucial role in
the accurate identification of target groups of patients, and it
might serve as a fundamental outcome and therapeutic response
measure. However, it should be noted that AEDs are primarily
applied for seizure control. Thus, their effect on inhibiting
epileptiform discharges (including IEA or SEA) is limited or
unknown. Furthermore, the identification of novel targets and
development of new drugs are crucial for the proper therapy of
hyperexcitability in cognitive disorders.
Potential Novel Directions
As we have described, many AEDs have been introduced to
the market over the recent decades and even more are in
development. Fundamentally, all AEDs have been designed or
optimized to restore an abnormal balance between excitatory
and inhibitory neurotransmission, which is a hallmark of
epilepsy. Most AEDs, especially those from the first generation,
lack selectivity and act on essential mediators of neuronal
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excitability such as ion channels, glutamate, or GABAA receptors.
These drugs exert widespread effects on neuronal networks
and cause a range of undesired side effects such as sedation
and cognitive deficits (Ortinski and Meador, 2004). Therefore,
newer antiepileptics that have more selective targets modulating
excitability in discrete neuronal circuits are better positioned
for potential treatment of SEA or IEA associated with various
neuropsychiatric disorders.
One such drug with a unique modulatory effect on neuronal
excitability exerted by binding to the synaptic vesicle protein
2A (SV2A) is LEV (Löscher et al., 2016). Compared to more
conventional AEDs, which typically act on postsynaptic receptors
or ion channels, levetiracetam tends to be better tolerated by
patients and does not induce strong sedative effect (Cramer
et al., 2003; Abou-Khalil, 2008). Interestingly, levetiracetam
has been initially developed as a cognitive enhancer after
chemical modification of its predecessor, piracetam. Several lines
of evidence indicate that low doses of levetiracetam improve
cognitive performance in both animal models and clinical
setting. These therapeutic activities of the drug are attributed
to modulation of hippocampal hyperactivity (Haberman et al.,
2017). Interestingly, levetiracetam is one of the few AEDs that
display clear-cut effect on IEA not only in patients with adult
(Stodieck et al., 2001) and childhood epilepsies (Larsson et al.,
2010), but also in children with ADHD (Bakke et al., 2011)
resulting in improvement in clinical symptoms (e.g., restless leg)
(Gagliano et al., 2011). Further, preclinical evidence indicates
that levetiracetam improves cognitive performance in models
of AD and schizophrenia (Sanchez et al., 2012; Koh et al.,
2018). There may be a connection with the mechanisms of
action of levetiracetam since several studies using SV2A PET
tracers show reduction in SV2A expression associated with
several neuropsychiatric and neurodegenerative diseases that
are associated with cognitive deficits (Heurling et al., 2019).
This was most clearly demonstrated in patients with AD
(Chen et al., 2018). It is believed that SV2A is a marker of
synaptopathy reflecting pathological changes in synaptic circuits
(e.g., hippocampus) associated with cognitive performance.
These observations have led to a number of clinical trials
exploring the potential of levetiracetam as treatment for cognitive
deficits associated with increased cortical activity or with SEA
in AD (Bakker et al., 2015; Vossel et al., 2016), and numerous
ongoing double-blind trials are going to conclude soon as well.
A promising potential therapeutic approach can be attributed
to subunit selective modulators of GABAA receptors, which have
discrete localization in the brain areas associated with SEA or
IEA. The key advantage of such compounds is their improved
safety and tolerability versus conventional, non-selective drugs
such as benzodiazepines. In this context, selective positive
allosteric modulators of alpha-5 subunit containing GABAA
receptors might have a potential to reduce the occurrence of
epileptiform discharges (Biagini et al., 2010), and studies have
shown promising effects on cognitive and memory performance
in animal models (Koh et al., 2013).
Abnormality in glutamate uptake is another important
mechanism that is shared by several neuropsychiatric diseases
that are associated with SEA and deficits in cognition
(O’Donovan et al., 2017). Recent work indicates that neuronal
hyperexcitability observed in the limbic regions in patients with
Alzheimer’s disease may be initiated by suppression of glutamate
reuptake and can trigger a vicious cycle of neurodegeneration
driven by β-amyloid (Zott et al., 2019). Therefore, restoration of
glutamate uptake by drugs increasing the expression or function
of excitatory amino acid transporter 2 (EAAT2) could find a novel
therapeutic indication for treatment of SEA or IEA associated
with various cognitive disorders (Fontana, 2015).
DISCUSSION
Cognitive disorders including NCDs, ASD, ADHD, and MS have
a high overall prevalence affecting approximately 40–50% of the
population. A common hallmark of these variable conditions
is the higher occurrence of epileptic seizures during the course
of the disease suggesting that hyperexcitation might play a role
in the pathomechanism of cognitive impairment (Tuchman and
Rapin, 2002; Austin and Caplan, 2007; Horváth et al., 2016).
Prevalence and impact of IEA and SEA are less investigated in
cognitive disorders in comparison to epileptic seizures. However,
the study of these phenomena might represent an important
future direction, since modern epileptology recognized that
isolated but frequent epileptic activity could compromise the
cognitive function of epilepsy patients more than epileptic
seizures (Berg, 2011).
Proper definition and/or distinction of IEA and SEA are
also missing, making it difficult to compare the results of
various prevalence studies. While the interictal terminology
postulates the presence of ictus (seizure), IEA is frequently used
to describe epileptiform activity without overt clinical seizures.
However, traditional epileptology recognizes epileptiform
discharges without detectable clinical or electrographic seizures
as benign EEG variants (Santoshkumar et al., 2009). From
the epileptological viewpoint, benign means that the detected
activity does not associate to clinically diagnosed epilepsy or
any other neurological or psychiatric disorder. However, in our
opinion, independency from seizures does not necessarily equal
to clinically benign behavior. A possible explanation is that
epileptiform discharges and epileptic seizures are consequences
and markers of increased cortical excitability, however, they
represent the different ends of the spectrum (Badawy et al.,
2009a). If network excitability exceeds a certain threshold,
the affected patient develops epileptic seizures and frequent
interictal epileptic discharges, leading to the diagnosis of epilepsy
(Dzhala and Staley, 2003). If it does not reach the threshold,
SEA is detectable and indicates increased excitability as a
general marker (Badawy et al., 2009b). Since more and more
neuropsychological and neuroimaging studies suggest that SEA
correlates with cognitive deterioration (Vossel et al., 2016), we
propose to reconsider the use of “benign” term for epileptiform
EEG graphoelements without detailed neuropsychological
investigation. In our review, we systematically separated the
two terms, IEA and SEA, and propose the exclusive use of
SEA for epileptiform events in the absence of proved epileptic
seizure. However, the distinction resulted in an important
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conclusion: SEA shows the similar characteristic as IEA
regarding the temporal, spatial characteristic, and the impact on
cognitive functions.
IEA and SEA both accumulate in sleep in AD patients (Vossel
et al., 2016; Horváth et al., 2017a), in ASD patients (Chez
et al., 2006), and in ADHD (Silvestri et al., 2007). IEA and
SEA both recorded mainly over the frontotemporal areas in AD
(Rao et al., 2009; Vossel et al., 2013, 2016; Cretin et al., 2016;
Sarkis et al., 2016; Horváth et al., 2018b), in ADHD (Lee et al.,
2016), and in ASD (Chez et al., 2006). Frequent occurrence of
interictal discharges associate to decreased therapeutic response,
poorer postsurgical outcome, and augmented cognitive decline
in epilepsy patients (Drane et al., 2016). Higher frequency of
IEA in SWS defines more prominent impairment in language
function of epileptic patients with ESES (Scheltens-de Boer,
2009). Therapeutic reduction in IEA improved the behavioral
problems of children with focal epilepsy (Pressler et al., 2005).
SEA is attached to two times faster progression of AD (Vossel
et al., 2016), higher prevalence of regression in ASD (Giannotti
et al., 2008; Stefanatos, 2008), elevated number of active lesions
in MS (Lebrun, 2006), and higher incidence of future seizures
in ADHD (Lee et al., 2016). Reduction in SEA by AED led
to 60% improvement in behavior scores in ADHD patients
(Bakke et al., 2011), improved cognitive scores in patients
with mild cognitive impairment (Bakker et al., 2015), and
significant positive changes in cognitive scores of ASD patients
(Hollander et al., 2001).
Based on literature overview, there are various ways how SEA
could have a detrimental effect on cognition. The common link
is the glutamatergic system that is compromised in all cognitive
disorders (Gonsette, 2008; Esposito et al., 2013). Increased
excitatory activity results in related excitotoxicity leading to
neurodegeneration of various neural structures in different
cognitive disorders (Mehta et al., 2013). In the neurodegenerative
process, epileptic discharges accelerate the accumulation of toxic
proteins (e.g., tau, amyloid) facilitating neural loss (Liang et al.,
2009; Dolev et al., 2013). These processes transform into a
vicious circle since misfolded proteins also induce excessive
release of glutamate (Ittner and Götz, 2011). The described
changes lead to a local hyperexcited neural network and
activation of compensatory remodeling mechanisms (Sutula,
2002). Remodeling can lead to the disconnection of the affected
structures to other functional networks (Engel et al., 2013). It
is supported by numerous studies demonstrating the loss of
distant connections in cognitive disorders (Liu et al., 2014).
Extending general excitability might have a crucial role in
the spreading of pathological proteins in the functional neural
networks of patients with NCDs (Pievani et al., 2011; Hoenig
et al., 2018). When large functional circuits are involved in
the pathological process, their function shows abnormalities,
and it is demonstrated by the alteration of sleep structure
(Palop and Mucke, 2010). Increasing number of epileptic
discharges leads to reduction in slow-wave sleep, overproduction
of dysfunctional, dummy sleep spindles, and finally loss of
sleep function in the memory encoding and consolidation
process (Malow, 2007; Halász et al., 2019). Since epileptic
discharges are crucial in the pathological process, modification
might have a novel therapeutic potential in cognitive disorders
(Bakker et al., 2015).
Rapidly emerging observations and data linking SEA or IEA
with a wide range of neuropsychiatric and cognitive disorders
open several previously unexplored therapeutic opportunities
that could be focused on targeting neuronal hyperexcitability.
In this context, an obvious solution would be application of
existing AEDs, which should be able to normalize such abnormal
neuronal activity. However, despite some promising results with
selected AEDs, this class of drugs is generally associated with
poor tolerability, narrow therapeutic window, and worsened
cognitive abilities. Therefore, a more selective and perhaps milder
modulation of neuronal excitability in discrete brain regions in
stratified subpopulation of patients with documented SEA or IEA
could lead to significant therapeutic benefits and become a novel
class of therapy for cognitive disorders.
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Horváth, A., Szűcs, A., Hidasi, Z., Csukly, G., Barcs, G., and Kamondi, A. (2018b).
Prevalence, semiology, and risk factors of epilepsy in Alzheimer’s disease: an
ambulatory EEG study. J. Alzheimers Dis. 63, 1045–1054. doi: 10.3233/jad-
170925
Hrdlicka, M., Komarek, V., Propper, L., Kulisek, R., Zumrova, A., Faladova, L., et al.
(2004). Not EEG abnormalities but epilepsy is associatd with autistic regresseion
and mental functioning in childhood autism. Eur. Child Adolesc. Psychiatry 13,
209–213.
Hu, Y., Jiang, Y., Hu, P., Ma, H., and Wang, K. (2016). Impaired social cognition
in patients with interictal epileptiform discharges in the frontal lobe. Epilepsy
Behav. 57(Pt A), 46–54. doi: 10.1016/j.yebeh.2016.01.027
Hughes, J. R., DeLeo, A. J., and Melyn, M. A. (2000). The Electroencephalogram
in Attention Deficit–Hyperactivity Disorder: Emphasis on Epileptiform
Discharges. Epilepsy Behav. 1, 271–277. doi: 10.1006/ebeh.2000.0073
Hughes, J. R., and Melyn, M. (2005). EEG and seizures in autistic children and
adolescents: further findings with therapeutic implications. Clin. EEG Neurosci.
36, 15–20. doi: 10.1177/155005940503600105
Hulst, H. E., Schoonheim, M. M., Van Geest, Q., Uitdehaag, B. M., Barkhof, F.,
and Geurts, J. J. (2015). Memory impairment in multiple sclerosis: relevance
of hippocampal activation and hippocampal connectivity. Mult. Scler. 21,
1705–1712. doi: 10.1177/1352458514567727
Ittner, L. M., and Götz, J. (2011). Amyloid-β and tau—a toxic pas de deux in
Alzheimer’s disease. Nat. Rev. Neurosci. 12, 67–72. doi: 10.1038/nrn2967
Jefferys, J. G., de La Prida, L. M., Wendling, F., Bragin, A., Avoli, M., Timofeev, I.,
et al. (2012). Mechanisms of physiological and epileptic HFO generation. Prog.
Neurobiol. 98, 250–264. doi: 10.1016/j.pneurobio.2012.02.005
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